Literature DB >> 26551711

Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.

Geoff Wells1.   

Abstract

The transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2) up-regulates the expression of a range of cytoprotective enzymes with antioxidant response elements in their promoter regions and thus can protect cells against oxidative damage. Increasing Nrf2 activity has been proposed as a therapeutic intervention in a range of chronic neurodegenerative conditions and cancer chemoprevention. One of the main mechanisms by which Nrf2 is negatively regulated involves an interaction with the ubiquitination facilitator protein, Kelch-like ECH-associated protein 1 (Keap1) that facilitates degradation of Nrf2. Inhibition of this process underlies the mode of action of a broad group of compounds that increase Nrf2 activity. A number of natural products, including the isothiocyanate sulforaphane, up-regulate Nrf2 by interacting with Keap1 in a covalent manner to stall its activity. Recently, a number of peptide and small molecule inhibitors of the protein-protein interaction (PPI) between Keap1 and Nrf2 have been described. These classes of compound have contrasting modes of action at the molecular level and there is emerging evidence that their biological activities have similarities and differences. This review describes the various classes of PPI inhibitor that have been described in the literature and the biological evaluations that have been performed.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  Kelch-like ECH-associated protein 1 (Keap1); drug discovery; nuclear factor erytheroid-2-related factor 2 (Nrf2); protein–protein interactions

Mesh:

Substances:

Year:  2015        PMID: 26551711     DOI: 10.1042/BST20150051

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  26 in total

Review 1.  Nrf2 at the heart of oxidative stress and cardiac protection.

Authors:  Qin M Chen; Anthony J Maltagliati
Journal:  Physiol Genomics       Date:  2017-11-29       Impact factor: 3.107

Review 2.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 3.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

4.  NRF2-targeted therapeutics: New targets and modes of NRF2 regulation.

Authors:  Montserrat Rojo de la Vega; Matthew Dodson; Eli Chapman; Donna D Zhang
Journal:  Curr Opin Toxicol       Date:  2016-10-12

5.  Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.

Authors:  Phillip R Lazzara; Brian P David; Aparna Ankireddy; Benjamin G Richardson; Katherine Dye; Kiira M Ratia; Sekhar P Reddy; Terry W Moore
Journal:  J Med Chem       Date:  2019-11-14       Impact factor: 7.446

Review 6.  Cancer metabolism: a therapeutic perspective.

Authors:  Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Nat Rev Clin Oncol       Date:  2016-05-04       Impact factor: 66.675

Review 7.  Activation of Nrf2 signaling by natural products-can it alleviate diabetes?

Authors:  Manuel Matzinger; Katrin Fischhuber; Elke H Heiss
Journal:  Biotechnol Adv       Date:  2017-12-28       Impact factor: 14.227

Review 8.  Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases.

Authors:  Yasuhiro Nakagami
Journal:  Oxid Med Cell Longev       Date:  2016-10-12       Impact factor: 6.543

9.  NRF2 as an Emerging Therapeutic Target.

Authors:  Ian M Copple; Albena T Dinkova-Kostova; Thomas W Kensler; Karen T Liby; W Christian Wigley
Journal:  Oxid Med Cell Longev       Date:  2017-01-31       Impact factor: 6.543

Review 10.  Nrf2 for cardiac protection: pharmacological options against oxidative stress.

Authors:  Qin M Chen
Journal:  Trends Pharmacol Sci       Date:  2021-07-28       Impact factor: 17.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.